Teriparatide
FDA ApprovedAn FDA-approved PTH analog researched for bone density improvement. One of the few anabolic bone treatments that actually builds new bone rather than just preventing loss.
Bone HealthLongevity
Half Life
~1 hour
Time to Results
3-6 months
Administration
SubQ injection
🐾 Griffin's Research Scorecard
Research Strength
Human Data
Animal Data
Long-Term Data
Beginner Friendly
Storage Difficulty
Injection FrequencyDaily
Cost$$$
🐾 Griffin Says...
One of the best-studied bone-building peptide drugs. Actually builds new bone rather than just slowing breakdown. The osteosarcoma concern from rat studies has not been seen in human clinical use, but dosing duration is still limited to 2 years.
Benefits
- Bone density improvement
- Fracture risk reduction
- Anabolic bone formation
- Osteoporosis treatment
Best For
- Bone density research
- Osteoporosis research
- Aging research
Body Systems
MusculoskeletalMetabolic
Mechanisms of Action
- PTH(1-34) receptor agonist
- Activates osteoblasts (bone-building cells)
- Net anabolic effect on bone with intermittent dosing
Side Effects
| Effect | Frequency | Severity |
|---|---|---|
| Nausea | Common | Mild |
| Dizziness | Uncommon | Mild |
| Leg cramps | Uncommon | Mild |
| Theoretical osteosarcoma risk (animal data) | Not seen in humans at clinical doses | Note |
Contraindications
Previous radiation to bones, elevated calcium, Paget's disease, children
Peptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open Calculator